{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:00Z","timestamp":1781650320902,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Congenital melanocytic nevus syndrome is a disorder characterized by postzygotic, mosaic NRAS Proto-Oncogene, GTPase mutations. Clinical manifestations include melanotic skin lesions and, optionally, central nervous system melanosis typically noted during early infancy. Affected individuals have an increased risk of developing malignant melanomas at an early age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We report a child with neurocutaneous melanosis due to this syndrome, who had innumerable nevi at birth and diffuse leptomeningeal thickening. He developed increased intracranial pressure at 4\u00a0weeks of age. The nucleoside analogue azacitidine and the Mitogen-Activated Protein Kinase, Kinase inhibitor trametinib were started at 6\u00a0weeks of age resulting in rapid reduction of leptomeningeal thickening. At 53\u00a0months of age, the patient still takes trametinib and has met all developmental milestones. There has been no evidence of melanoma, and he exhibits minimal residual leptomeningeal changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our best knowledge, this is the first child with this syndrome who has undergone successful therapy to reduce leptomeningeal thickening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40348-026-00233-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T03:12:25Z","timestamp":1776049945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of azacitidine and trametinib against leptomeningeal melanosis associated with congenital melanocytic nevus syndrome"],"prefix":"10.1186","volume":"13","author":[{"given":"Lina","family":"Raljevi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Komlosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Feige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eckenweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroun Bel Hadj","family":"Jrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Has","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"9","key":"233_CR1","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1038\/jid.2013.70","volume":"133","author":"VA Kinsler","year":"2013","unstructured":"Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S et al (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 133(9):2229\u20132236","journal-title":"J Invest Dermatol"},{"issue":"6","key":"233_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1469-8749.2012.04275.x","volume":"54","author":"V Ramaswamy","year":"2012","unstructured":"Ramaswamy V, Delaney H, Haque S, Marghoob A, Khakoo Y (2012) Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Dev Med Child Neurol 54(6):563\u2013568","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"233_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2350\/14-10-1566-OA.1","volume":"18","author":"CM Salgado","year":"2015","unstructured":"Salgado CM, Basu D, Nikiforova M, Bauer BS, Johnson D, Rundell V et al (2015) BRAF mutations are also associated with neurocutaneous melanocytosis and large\/giant congenital melanocytic nevi. Pediatr Dev Pathol 18(1):1\u20139","journal-title":"Pediatr Dev Pathol"},{"issue":"3","key":"233_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjd.13898","volume":"173","author":"R Waelchli","year":"2015","unstructured":"Waelchli R, Aylett SE, Atherton D, Thompson DJ, Chong WK, Kinsler VA (2015) Classification of neurological abnormalities in children with congenital melanocytic naevus syndrome identifies magnetic resonance imaging as the best predictor of clinical outcome. Br J Dermatol 173(3):739\u2013750","journal-title":"Br J Dermatol"},{"issue":"1","key":"233_CR5","doi-asserted-by":"publisher","first-page":"16442","DOI":"10.1038\/s41598-023-43829-w","volume":"13","author":"M Takiya","year":"2023","unstructured":"Takiya M, Fushimi Y, Sakamoto M, Yoshida T, Ueno K, Nakajima S et al (2023) Incidence of neurocutaneous melanosis in Japanese pediatric patients with congenital melanocytic nevi. Sci Rep 13(1):16442","journal-title":"Sci Rep"},{"issue":"4","key":"233_CR6","doi-asserted-by":"publisher","first-page":"e30859","DOI":"10.1002\/pbc.30859","volume":"71","author":"M Abele","year":"2024","unstructured":"Abele M, Forchhammer S, Eigentler TK, Popescu A, Maschke L, Lohse J et al (2024) Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: a rare but fatal condition. Pediatr Blood Cancer 71(4):e30859","journal-title":"Pediatr Blood Cancer"},{"issue":"5 Pt 1","key":"233_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0190-9622(91)70115-I","volume":"24","author":"JN Kadonaga","year":"1991","unstructured":"Kadonaga JN, Frieden IJ (1991) Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 24(5 Pt 1):747\u2013755","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"233_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.sder.2004.01.007","volume":"23","author":"HS Makkar","year":"2004","unstructured":"Makkar HS, Frieden IJ (2004) Neurocutaneous melanosis. Semin Cutan Med Surg 23(2):138\u2013144","journal-title":"Semin Cutan Med Surg"},{"issue":"4","key":"233_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00006534-200104010-00005","volume":"107","author":"RD Foster","year":"2001","unstructured":"Foster RD, Williams ML, Barkovich AJ, Hoffman WY, Mathes SJ, Frieden IJ (2001) Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children. Plast Reconstr Surg 107(4):933\u2013941","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"233_CR10","doi-asserted-by":"publisher","first-page":"e29468","DOI":"10.1002\/pbc.29468","volume":"69","author":"KM Hanft","year":"2022","unstructured":"Hanft KM, Hamed E, Kaiser M, Wurtemberger J, Schneider M, Pietsch T et al (2022) Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma. Pediatr Blood Cancer 69(4):e29468","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"233_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/bjc.2017.49","volume":"116","author":"VA Kinsler","year":"2017","unstructured":"Kinsler VA, O\u2019Hare P, Jacques T, Hargrave D, Slater O (2017) MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. Br J Cancer 116(8):990\u2013993","journal-title":"Br J Cancer"},{"key":"233_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/2051-5960-2-41","volume":"2","author":"HV K\u00fcsters-Vandevelde","year":"2014","unstructured":"K\u00fcsters-Vandevelde HV, Willemsen AE, Groenen PJ, K\u00fcsters B, Wesseling ML, Djafarihamedani M et al (2014) Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun 2:41","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"233_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07218.x","volume":"155","author":"S Krengel","year":"2006","unstructured":"Krengel S, Hauschild A, Schafer T (2006) Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 155(1):1\u20138","journal-title":"Br J Dermatol"},{"issue":"7375","key":"233_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature10539","volume":"480","author":"C Bertolotto","year":"2011","unstructured":"Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94\u201398","journal-title":"Nature"},{"issue":"7375","key":"233_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10630","volume":"480","author":"S Yokoyama","year":"2011","unstructured":"Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99\u2013103","journal-title":"Nature"},{"key":"233_CR16","doi-asserted-by":"crossref","unstructured":"Vergani E, Frigerio S, Dugo M, Devecchi A, Feltrin E, De Cecco L et al (2021) Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients. Genes (Basel) 12(9):1440","DOI":"10.3390\/genes12091440"},{"issue":"7","key":"233_CR17","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/jid.2015.61","volume":"135","author":"M Lauss","year":"2015","unstructured":"Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J et al (2015) Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol 135(7):1820\u20131828","journal-title":"J Invest Dermatol"},{"issue":"3","key":"233_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/jid.2014.425","volume":"135","author":"C Lu","year":"2015","unstructured":"Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z et al (2015) The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol 135(3):816\u2013823","journal-title":"J Invest Dermatol"},{"issue":"1","key":"233_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/JID.2015.374","volume":"136","author":"Y Fan","year":"2016","unstructured":"Fan Y, Lee S, Wu G, Easton J, Yergeau D, Dummer R et al (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136(1):339\u2013342","journal-title":"J Invest Dermatol"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-026-00233-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-026-00233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:53:46Z","timestamp":1781646826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40348-026-00233-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1186\/s40348-026-00233-4","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.Informed consent for the experimental treatment with azacitidine and trametinib and for publication has been obtained from the parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}